Update on the safety profile of certolizumab pegol in rheumatoid arthritis: An integrated analysis from clinical trials
Antibodies, Monoclonal, Humanized
Immunoglobulin Fab Fragments
No new or unexpected safety signals associated with CZP emerged in this updated long-term safety analysis. While SIE rates were higher for CZP than for placebo in RCT, the rate decreased with continued exposure to CZP. These rates are consistent with data previously reported for CZP and other tumour necrosis factor inhibitors.